Efficacy Study News Today

~67% eye preservation rate (6 of 9 enucleation patients) with darovasertib monotherapy neoadjuvant uveal melanoma treatment Median tumor shrinkage (maximum...

/PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted...

GSK's Nucala approved in China for use in severe asthma

The approval makes enzalutamide the first and only androgen receptor-signaling inhibitor approved for the treatment of nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastatic.

Approximately 70 to 300 million individuals worldwide are living with myasthenia gravis, an antibody-mediated autoimmune disorder that adversely affects neuromuscular junction function.

GSK ViiV Healthcare's Apretude authorised for HIV prevention in EU

/PRNewswire/ -- Lindamood-Bell, in collaboration with the American Institutes for Research® (AIR®), has been awarded funding for "An Efficacy Study of the...

### Key messages > New immunomodulatory therapeutics hold promise for the future treatment of myasthenia gravis, say DeHart-McCoyle and colleagues Myasthenia gravis is an antibody mediated autoimmune disorder affecting the function of the neuromuscular junction, leading to fluctuating weakness of

Tolebrutinib is an Bruton tyrosine kinase (BTK) inhibitor that is being investigated for use in patients who have relapsing multiple sclerosis (MS); investigators presented safety data from a long-term extension study of the phase 2b dose-finding trial.

Two-year data on magnetic resonance imaging (MRI), efficacy, and safety findings from the long-term safety extension study of the investigational Bruton tyrosine kinase (BTK) inhibitor tolebrutinib for relapsing multiple sclerosis were presented in a pair of posters at the American Academy of Neurology 2023 annual meeting.